Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
> home > Products > Peptides > Blocking Peptides > Neurogenin1 (NeuroG1) Antibody (N-term) Blocking peptide
Neurogenin1 (NeuroG1) Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q92886 |
|---|---|
| Other Accession | NP_006152 |
| Clone Names | 2120411 |
| Other Names | Neurogenin-1, NGN-1, Class A basic helix-loop-helix protein 6, bHLHa6, Neurogenic basic-helix-loop-helix protein, Neurogenic differentiation factor 3, NeuroD3, NEUROG1, BHLHA6, NEUROD3, NGN, NGN1 |
|---|---|
| Target/Specificity | The synthetic peptide sequence used to generate the antibody AP2022a was selected from the N-term region of human NeuroG1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | NEUROG1 |
|---|---|
| Synonyms | BHLHA6, NEUROD3, NGN, NGN1 |
| Function | Acts as a transcriptional regulator. Involved in the initiation of neuronal differentiation. Activates transcription by binding to the E box (5'-CANNTG-3'). Associates with chromatin to enhancer regulatory elements in genes encoding key transcriptional regulators of neurogenesis (By similarity). |
| Cellular Location | Nucleus. |
| Tissue Location | Expression restricted to the embryonic nervous system EMBL; U63842; AAB37575.1; -; Genomic_DNA EMBL; BT019366; AAV38173.1; -; mRNA EMBL; CH471062; EAW62214.1; -; Genomic_DNA EMBL; BC008687; AAH08687.1; -; mRNA EMBL; BC028226; AAH28226.1; -; mRNA CCDS; CCDS4187.1; - RefSeq; NP_006152.2; NM_006161.2 SMR; Q92886; - BioGRID; 110835; 8 IntAct; Q92886; 2 STRING; 9606.ENSP00000317580; - iPTMnet; Q92886; - PhosphoSitePlus; Q92886; - BioMuta; NEUROG1; - DMDM; 37538313; - PaxDb; Q92886; - PeptideAtlas; Q92886; - PRIDE; Q92886; - ProteomicsDB; 75570; - Antibodypedia; 26408; 572 antibodies DNASU; 4762; - Ensembl; ENST00000314744; ENSP00000317580; ENSG00000181965 GeneID; 4762; - KEGG; hsa:4762; - UCSC; uc003lax.3; human CTD; 4762; - DisGeNET; 4762; - EuPathDB; HostDB:ENSG00000181965.5; - GeneCards; NEUROG1; - HGNC; HGNC:7764; NEUROG1 HPA; ENSG00000181965; Group enriched (brain, retina, testis) MIM; 601726; gene neXtProt; NX_Q92886; - OpenTargets; ENSG00000181965; - PharmGKB; PA31569; - eggNOG; KOG3898; Eukaryota GeneTree; ENSGT00940000162170; - HOGENOM; CLU_097959_0_0_1; - InParanoid; Q92886; - KO; K09081; - OMA; QCAPCLP; - OrthoDB; 1524429at2759; - PhylomeDB; Q92886; - TreeFam; TF315153; - PathwayCommons; Q92886; - SIGNOR; Q92886; - BioGRID-ORCS; 4762; 4 hits in 887 CRISPR screens GeneWiki; NEUROG1; - GenomeRNAi; 4762; - Pharos; Q92886; Tbio PRO; PR:Q92886; - Proteomes; UP000005640; Chromosome 5 RNAct; Q92886; protein Bgee; ENSG00000181965; Expressed in subventricular zone (outer) (primate) and 19 other tissues ExpressionAtlas; Q92886; baseline and differential Genevisible; Q92886; HS GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB GO; GO:0043204; C:perikaryon; IEA:Ensembl GO; GO:0003682; F:chromatin binding; ISS:UniProtKB GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB GO; GO:0070888; F:E-box binding; IDA:CAFA GO; GO:0042803; F:protein homodimerization activity; IDA:CAFA GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:CAFA GO; GO:0031223; P:auditory behavior; IGI:CAFA GO; GO:0045165; P:cell fate commitment; IEA:Ensembl GO; GO:0090102; P:cochlea development; IGI:CAFA GO; GO:0090103; P:cochlea morphogenesis; IGI:CAFA GO; GO:0097094; P:craniofacial suture morphogenesis; IGI:CAFA GO; GO:0048806; P:genitalia development; IGI:CAFA GO; GO:0035112; P:genitalia morphogenesis; IGI:CAFA GO; GO:1905748; P:hard palate morphogenesis; IGI:CAFA GO; GO:0048839; P:inner ear development; IGI:CAFA GO; GO:0042472; P:inner ear morphogenesis; IGI:CAFA GO; GO:0098583; P:learned vocalization behavior; IGI:CAFA GO; GO:0071626; P:mastication; IGI:CAFA GO; GO:1901078; P:negative regulation of relaxation of muscle; IGI:CAFA GO; GO:1905747; P:negative regulation of saliva secretion; IGI:CAFA GO; GO:0007399; P:nervous system development; TAS:ProtInc GO; GO:0050885; P:neuromuscular process controlling balance; IGI:CAFA GO; GO:0030182; P:neuron differentiation; IEA:Ensembl GO; GO:0030432; P:peristalsis; IGI:CAFA GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; ISS:UniProtKB GO; GO:0031536; P:positive regulation of exit from mitosis; IEA:Ensembl GO; GO:0045666; P:positive regulation of neuron differentiation; ISS:UniProtKB GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB GO; GO:0048634; P:regulation of muscle organ development; IGI:CAFA GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:ProtInc GO; GO:0007356; P:thorax and anterior abdomen determination; IGI:CAFA GO; GO:0021559; P:trigeminal nerve development; IGI:CAFA GO; GO:0021650; P:vestibulocochlear nerve formation; IGI:CAFA CDD; cd00083; HLH; 1 DisProt; DP00672; - Gene3D; 4.10.280.10; -; 1 InterPro; IPR011598; bHLH_dom InterPro; IPR036638; HLH_DNA-bd_sf InterPro; IPR032653; Ngn1 PANTHER; PTHR19290:SF130; PTHR19290:SF130; 1 Pfam; PF00010; HLH; 1 SMART; SM00353; HLH; 1 SUPFAM; SSF47459; SSF47459; 1 PROSITE; PS50888; BHLH; 1 1: Evidence at protein level; Activator; Developmental protein; Differentiation; DNA-binding; Neurogenesis; Nucleus; Reference proteome; Transcription; Transcription regulation CHAIN 1..237 /note="Neurogenin-1" /id="PRO_0000127396" DOMAIN 92..144 /note="bHLH" /evidence="ECO:0000255|PROSITE-ProRule:PRU00981" CONFLICT 51 /note="G -> S (in Ref. 1; AAB37575)" /evidence="ECO:0000305" SEQUENCE 237 AA; 25718 MW; E3702A0B3408D567 CRC64; MPARLETCIS DLDCASSSGS DLSGFLTDEE DCARLQQAAS ASGPPAPARR GAPNISRASE VPGAQDDEQE RRRRRGRTRV RSEALLHSLR RSRRVKANDR ERNRMHNLNA ALDALRSVLP SFPDDTKLTK IETLRFAYNY IWALAETLRL ADQGLPGGGA RERLLPPQCV PCLPGPPSPA SDAESWGSGA AAASPLSDPS SPAASEDFTY RPGDPVFSFP SLPKDLLHTT PCFIPYH |
Research Areas
Citations (0)
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
Submit your citation using an Abcepta antibody to
info@abcepta.com, and receive a free "I Love Antibodies" mug.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Application Protocols
Provided below are standard protocols that you may find useful for product applications.
Background
Basic helix-loop-helix (bHLH) proteins are transcription factors involved in determining cell type during development. NeuroG1 is a bHLH protein with dual cell-fate specification roles. It functions during neurogenesis, and it has also been shown to inhibit the differentiation of neural stem cells into astrocytes. NeuroG1 promotes neurogenesis by functioning as a transcriptional activator, yet it inhibits astrocyte differentiation by compartmentalizing the CREB-binding protein transcription complex away from astrocyte differentiation genes and by inhibiting STAT transcription factors essential for gliogenesis.
References
Tamimi, R.M., et al., Genomics 40(2):355-357 (1997).McCormick, M.B., et al., Mol. Cell. Biol. 16(10):5792-5800 (1996).
Abcepta welcomes feedback from its customers.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
$ 277.78
Cat# BP2022a
Ordering Information
United States
AlbaniaAustraliaAustriaBelgiumBosnia & HerzegovinaBrazilBulgariaCanadaCentral AmericaChinaCroatiaCyprusCzech RepublicDenmarkEstoniaFinlandFranceGermanyGreeceHong KongHungaryIcelandIndiaIndonesiaIrelandIsraelItalyJapanLatviaLithuaniaLuxembourgMacedoniaMalaysiaMaltaNetherlandsNew ZealandNorwayPakistanPolandPortugalRomaniaSerbiaSingaporeSlovakiaSloveniaSouth AfricaSouth KoreaSpainSwedenSwitzerlandTaiwanTurkeyUnited KingdomUnited StatesVietnamWorldwideOthers
USA Headquarters
(888) 735-7227 / (858) 622-0099 or (858) 875-1900
Other Products
Shipping Information
Domestic orders (in stock items)
Shipped out the same day. Orders placed after 1 PM (PST) will ship out the next business day.
International orders
Contact your local distributors
